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Abstract
Background: Musculoskeletal (MSK) conditions are a major source of morbidity and disability. There is a lack of
global comparable data on the burden of MSK conditions in children and young people. Our aim was to estimate
the global prevalence of three MSK conditions - Talipes Equinovarus (Clubfoot), Juvenile Idiopathic Arthritis (JIA)
and Juvenile Systemic Lupus Erythematosus (JSLE).
Methods: Using reported prevalence rates, age-stratified population data within the World Bank Data Bank in 2017
and United Nations country classification, we estimated the prevalence of these MSK conditions in < 5 year olds
(clubfoot) and < 16 year olds (JIA and JSLE) across the world.
Results: We estimated that in 2017, there were ~ 675,061 < 5 year olds with clubfoot among 675,100,000 < 5 year
olds, ~ 2,069,246 < 16 year olds with JIA and ~ 206,931 < 16 year olds with JSLE per 2,069,000,000 < 16 year olds,
totalling ~ 2,951,238 with one of these conditions. Disease prevalence was greatest in Asia (South Asia), followed by
Africa, Americas, Europe and Oceania.
Conclusions: An estimated 3 million children and young people globally are currently living with either clubfoot,
JIA or JSLE; many in Asia and Africa. Further work is needed urgently to engage with global stakeholders to work
together to improve access to effective care for the many who are affected and reduce the otherwise adverse
lifelong impact on their health, quality of life and the impact on society.
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Background
The importance of musculoskeletal conditions in children
and young people
Musculoskeletal (MSK) conditions are a leading cause of
disability and morbidity and encompass conditions
within rheumatology and orthopaedics as well as being
the consequences of trauma and obesity. MSK
conditions in adults are a major contributor to the global
non-communicable diseases (NCDs) burden [1] and a
priority for the global community to address [2–4] in
the World Health Organisation (WHO) strategy for Uni-
versal Health Coverage [5]. Compared to 43.9% in 1990,
NCDs accounted for 61.4% of global disability adjusted
life years (DALYs) in the recent Global Burden of Dis-
ease report [1, 4] with the shift in disease burden from
communicable to NCDs being more apparent in Low
and Middle Resource Income countries (LRIC, MRIC).
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What is less clear, however, is the global burden of
MSK conditions for individuals under the age of 18
years; there is a paucity of population data, especially in
the most populated parts of the world [4]. In the UK, it
is estimated that 1 in 8 children are affected by MSK
conditions [6] - many are self-limiting or related to
trauma although there are also serious MSK conditions
with potential to be life threatening or cause severe dis-
ability if untreated. With advances in treatments for
many MSK diseases, it is more important than ever to
address inequity in access to care and to include chil-
dren (who represent at least 20% of the global popula-
tion, [7]) in strategies to reduce MSK disability across
the life course.
The purpose of our work is to inform the ‘bigger pic-
ture’ and to estimate global prevalence of three MSK
conditions in children and young people using popula-
tion based methods [7]. This is a pragmatic approach in
the absence of robust global population studies and pro-
vides a novel perspective to inform dialogue to address
unmet need.
Methods
MSK conditions
The chosen MSK conditions are Talipes Equinovarus
(‘Clubfoot’), Juvenile Idiopathic Arthritis (JIA) and
Juvenile Systemic Lupus Erythematosus (JSLE). The
rationale for their inclusion was the evidence base of
estimated prevalence rates, the importance of early
diagnosis, and the importance of access to the right
care to optimise clinical outcomes.
Clubfoot can affect one or both feet, commonly occur-
ring in isolation, but may also be associated with other
congenital anomalies [8, 9]. Clubfoot in most cases can
be effectively treated using the validated Ponseti method
[10, 11] but without appropriate treatment can result in
pain, disability and social handicap [12]. In this report,
we use the term ‘clubfoot’ to represent isolated struc-
tural clubfoot. We use the term ‘prevalence’ in the under
5 year old age group, rather than incidence, as we do not
know how many affected foetuses may have been ‘lost’
through early miscarriage and the condition is congeni-
tal. Prevalence rates of clubfoot vary between countries
and racial groups; for this study we used an estimated
prevalence rate of 1 in 1000 children based on reports
from Europe [8] and North America [9].
JIA is a heterogeneous group of diseases with mark-
edly improved clinical outcomes since the introduction
of highly effective immunosuppressives and specialist
care [13, 14]. Prevalence studies are predominantly re-
ported from Caucasian populations in Europe, North
America and Australia with further evidence of variance
in the prevalence of JIA subtypes in different ethnic
groups and countries [15–20]; to our knowledge there
are no population based studies from Africa or Asia.
Such variation in prevalence rates reflect historical chal-
lenges in disease classification, ascertainment and refer-
ral biases but may also reflect true disease variation
within different ethnic populations [15]. For the purpose
of our work, we have used the estimated prevalence of 1
in 1000 based on the pooled prevalence data [15] and
have not attempted to estimate JIA subtypes, or address
variation by age, gender or ethnicity.
JSLE is a multisystem disease with serious, potentially
life threatening organ involvement [21–24] and reported
to be more common and severe in non-Caucasians with
worse clinical outcomes [21, 23, 25–27]; to our know-
ledge there are no population based prevalence studies
in Asia or Africa. For the purpose of this study, we have
assumed a prevalence of 10 in 100,000 based on the
United States (US) Medicaid programme covering a
multi-racial population [22]; we have not attempted to
address variation in prevalence estimates by age, gender
or ethnicity.
Data sources
The World Bank Group (WBG) [7] online Databank
provides free access to a range of datasets related to glo-
bal development which can be downloaded in a range of
formats. For our study, population data for 2017 were
downloaded from the ‘Population estimates and projec-
tions database’ within the WBG Databank for every
country available within the database (n = 217) and
stratified by age in single years from 0 to 15 years for
males and females separately. The total population of
countries (all ages) was extracted similarly. Information
on geographic regions and sub-regions for classification
of countries, was taken from the United Nations (UN)
Statistics Division [28].
Data management
Each country was manually assigned to its correspond-
ing region and sub-region as classified by the UN [28]
with the exception of Cyprus and Turkey which were
classified as being in - Asia, Western Asia - by the UN
[28] - but were re-classified to - Europe, Southern Eur-
ope - for the purposes of our analysis. Grouping of
countries within their respective regions and sub-regions
is shown in Additional file 1: Appendix A. Countries
within the WBG Databank, differ from those within the
UN Statistics Division. Countries with missing popula-
tion data or a missing UN regional classification were
excluded from our datasets and not included in any fur-
ther analysis.
Estimation of prevalence rates
The population of < 5 years olds was calculated by sum-
ming the population within each age band from 0 to 4
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years for males and females separately. These were then
summed to give the total population of all children < 5
years old by country, region and sub-region. The same
process was undertaken to calculate the population of <
16 year olds using the population within each age band
from 0 to 15 years. Estimated prevalences were calcu-
lated for 2017 using the reported prevalence rates of 1/
1000 for clubfoot, 1/1000 for JIA and 10/100,000 for
JSLE and the 2017 population of < 5 year olds (for club-
foot) and < 16 year olds (for JIA and JSLE) by country,
region and sub-region using the following equation: Esti-
mated prevalence of MSK condition = Reported preva-
lence rate X Population. Data management and analysis
were undertaken within Microsoft Excel and Stata ver-
sion 14.
Results
Table 1 summarises the data available in 2017 that were
used to establish the global prevalences of the selected
MSK conditions. Over 200 countries and almost 7.5 bil-
lion people (with just over 2 billion < 16 year olds) were
included in the analysis. Across all included countries,
we estimated over 675,000 children < 5 years of age liv-
ing with clubfoot, over 2 million < 16 year olds with JIA
and over 200,000 with JSLE. Overall, we estimated nearly
3 million children were living with one of these condi-
tions in 2017 (Fig. 1) with the data stratified by UN re-
gion and sub-region (Figs. 2 and 3 respectfully). Further
analysis described the relative prevalence in different
countries within the UN regions and sub-regions (Add-
itional file 1: Appendix B). Asia (in particular Southern
and Eastern Asia) had the highest estimated numbers of
individuals with clubfoot, JIA and JSLE followed by
Africa, the Americas and Europe, with Oceania having
the lowest estimated numbers for all three conditions.
The distribution across each UN region can be seen in
Fig. 2. Most clubfoot burden was concentrated across
three sub-regions: Southern Asia, Eastern Asia and East-
ern Africa, whilst 51% of both JIA burden and JSLE bur-
den was concentrated across these same regions. When
further stratifying analysis by sub-region, we found
Southern Asia had the highest estimated case numbers
for clubfoot (176,462); 26% of clubfoot burden was dis-
tributed within this sub-region. This was followed by
Eastern Asia (95,085 estimated cases, 14%) and Eastern
Africa (66,158 estimated cases, 10%). Southern Asia also
had the highest estimated numbers of JIA cases (571,
572) with 28% of disease burden distributed across this
sub-region. This was followed by Eastern Asia (297,333
estimated cases, 14%) and Eastern Africa (187,787 esti-
mated cases, 9%). A similar pattern was seen for JSLE
with 57,157 estimated cases in Southern Asia, represent-
ing 28% of disease burden, followed by Eastern Asia (29,
733 estimated cases, 14%) and Eastern Africa (18,779 es-
timated cases, 9%). The data are presented for each
country (Additional file 1: Appendix C). In absolute
terms, the countries with highest numbers of CYP with
the exemplar conditions reflect the overall population
sizes; in descending order these are India, China,
Nigeria, Pakistan, Indonesia and the United States.
Discussion
Our work has taken a pragmatic approach to estimate
global prevalence of three MSK conditions and using
WBG population data from 2017, suggests that nearly 3
million individuals have at least one of clubfoot, JIA or
Table 1 Summary of the World Bank Group Data (2017) used in the analysis
Variable N
Countries listed in World Bank Group Data 217
Countries with missing UN region data 2
Countries with missing World Bank population data 23
Countries excluded from estimate calculations (data not available) 25
Countries included in analysis 192
Regions listed in UN Statistics Division 5
Sub-regions listed in UN Statistics Division 22
Total population < 5 years old across all countries with population data
Male: Female
6.75 × 10^8
(675,100,000)
1.07:1.00
Total population < 16 years old across all countries with population data
Male: Female
2.07 × 10^9
(2,069,000,000)
1.07:1.00
Total population across all countries included in analysis 7.49 × 10^9
(7,494,205,912)
Proportion of total population < 5 years old 9.01%
Proportion of population < 16 years old 27.61%
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JSLE. Given that our analysis is limited to three condi-
tions and we have not included trauma, then clearly the
true MSK prevalence around the world is much higher.
If we were to use our pragmatic model with the 2017 es-
timated global population of 2.07 × 109 young people
aged under 16 years and a reported prevalence 1 in 8 [6]
having an MSK presentation of one kind or another,
then we estimate nearly 26 million individuals are likely
to be affected.
This work aims to inform dialogue about the MSK
contribution to NCDs in children and the need for strat-
egies to include a life course approach. In the absence of
robust population based studies from many parts of the
world, our work demonstrates many are living with
MSK conditions, mostly in Asia and Africa and reflect-
ing regions with high populations.
This information is important as the regions with
highest estimates of children affected do not have robust
Fig. 1 Total estimated number of cases of clubfoot, JIA and JSLE across all countries included in analysis, 2017. The totals here are the sums of
individual country data and will therefore be slightly different to the total when calculated by summing region data or sub-region data in
subsequent figures due to rounding error
Fig. 2 Estimated number of children in 2017 with clubfoot, JIA and JSLE by UN region
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population studies and many of the countries are LRIC.
Consequently, it is likely that many affected children
have little or no access to specialist care. Recent evi-
dence reports worse clinical outcomes in JIA for coun-
tries with lower Gross Domestic Product [16]; it is
possible that the same will be true for JSLE and clubfoot.
JSLE remains a major cause of mortality in many parts
of the world with late presentation and lack of treat-
ments being available [18, 29, 30]. MSK conditions may
be less prevalent than other NCDs such as diabetes [31]
or inflammatory bowel disease [32], but the key message
for public health systems is that the selected MSK condi-
tions are treatable and disability can be largely avoided.
In the case of clubfoot, the interventions is largely
through physiotherapy at relatively low cost and signifi-
cant benefit [11] and for many rheumatic diseases
significant improvement can be observed with immuno-
suppressive treatments [13].
To address unmet need, there are many challenges to
consider including awareness, workforce capacity,
models of health care, and funding [18, 30, 33–35]. The
WHO Global Burden Disability 2018 report [1] describes
the health care workforce shortage in many parts of the
world as being critical, more so in Asia and Africa and
for the care of children [36]. Such parts of the world are
most vulnerable to the burden of MSK disease given
more ‘pressing’ health care need to address poverty, in-
fection and malnutrition in health care resource limited
environments.
There are several limitations in our study. We based
our estimates on available reported prevalence rates for
each condition and assumed stable prevalence over time.
There is a spectrum of prevalence rates for JIA largely
from Caucasian populations [15]; we used an average
prevalence of 1 in 1000 and this may not be representa-
tive in terms of population or demographics (age stratifi-
cation, gender or ethnicity) of individual countries. We
did not attempt to address the reported variation in dis-
ease phenotype across racial groups in JIA [16, 17] or
JSLE [25] or clubfoot [9]. Additionally, our calculations
were subject to rounding error. Despite these limitations,
we consider the data to be pragmatic estimates of the se-
lected conditions and if anything, likely to be an under-
estimate. Comparison with historical population datasets
for JIA from the UK [37] and Scandinavia [20] suggest
that our estimates are reasonable, at least for countries
Fig. 3 Estimated musculoskeletal conditions prevalence in 2017 by UN region and sub-region
Dave et al. Pediatric Rheumatology           (2020) 18:49 Page 5 of 7
with predominantly Caucasian populations. Our work
highlights need for robust epidemiological data, espe-
cially from Africa and Asia, to inform dialogue about
MSK burden in children and to include other MSK con-
ditions such as Slipped Capital Femoral Epiphysis
(SCFE) [38] where there is evidence of delay and early
(surgical) intervention to improve clinical outcomes.
In conclusion, our work suggests that there are many
children and young people with the selected MSK condi-
tions around the world and many in regions challenged
by limited resources and other health care problems.
The Paediatric Global MSK Task Force [39] aims to
raise awareness about the inequity in access to right care
and a timely need for intervention. We hope that this
study will facilitate dialogue with key stakeholders to le-
verage action.
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